Microarray Ltd

Manchester, United Kingdom

Microarray Ltd

Manchester, United Kingdom

Time filter

Source Type

LONDON, May 10, 2017 /PRNewswire/ -- Multiplex Assays Market by Type {Nucleic Acid-Based Multiplex Assays (Planar Nucleic Acid Assays and Bead-Based Nucleic Acid Assays), Protein-Based Multiplex Assays (Planar Protein Assays and Bead-Based Protein Assays), and Other Multiplex Assays}, Product {Multiplex Assay Reagents & Consumables, Multiplex Assay Accessories & Instruments, and Multiplex Assay Software & Services}, Technology {Multiplex PCR, Multiplex Protein Microarray, and Other Technologies}, Application {Companion Diagnostics, Research & Development (Drug Development and Biomarker Discovery & Validation), Clinical Diagnostics (Cancer, Infectious Diseases, Cardiac Diseases, Autoimmune Diseases, Alzheimer's Disease, and Other Diseases)}, and End User {Hospitals, Clinical Laboratories, Research Institutes, and Pharmaceuticals & Biotechnological Companies} - Global Opportunity Analysis and Industry Forecast, 2014-2022 Download the full report: https://www.reportbuyer.com/product/4883720/ Intraocular lenses (IOLs) are a type of ophthalmic implants, which are used in surgeries pertaining to eyes. IOLs are synthetic lenses implanted inside the eye that substitute the focusing power of a natural lenses, which are surgically removed. These are used to treat myopia, astigmatism, or cataracts. The global intraocular lens market generated $3,306 million in 2015, and is projected to reach $4,973 million by 2022, registering a CAGR of 7.0% during the study period. In terms of volume, the market is expected to grow at a CAGR of 7.1%. This is attributed to rise in geriatric population, increase in prevalence of cataract, and rise in initiatives taken by government to eliminate avoidable blindness. Moreover, rise in adoption of premium lens owing to their enhanced visual performance ensures reduced rates of astigmatism, thus supplementing the growth of the market. However, unfavorable reimbursement scenario for premium lens and postoperative complications such as refractive errors are expected to restrain the market growth. The intraocular lens market is segmented based on type, material, end user, and geography. On the basis of type, the market is bifurcated into monofocal and premium intraocular lens. The premium intraocular lens is sub-segmented into toric, multifocal, accommodating, and others (blue light filtering, phakic, and aspheric intraocular lens). By material, the market is categorized into polymethylmethacrylate (PMMA), silicone, and hydrophobic acrylic. According to end user, it is divided into hospitals, ambulatory surgical centers, ophthalmology clinics, and eye research institutes. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Prominent players adopted product development and product launches & approvals as their key developmental strategies to expand their product portfolio. For instance, in July 2016, Abott Medical Optics (now acquired by Johnson & Johnson) received FDA approval for the use of Tecnis Symfony Intraocular lenses for the treatment of cataract. KEY BENEFITS This report provides an extensive analysis of the current and emerging market trends and dynamics in the global intraocular lens market. This study provides the competitive landscape of the global market to predict the competitive environment across geographies. This report entails the detailed quantitative analysis of the current trends and future estimations to identify the prevailing opportunities. Comprehensive analysis of factors that drive and restrict the market growth is provided in the report. Region- and country-wise analysis is provided to understand the market trends and dynamics. KEY MARKET SEGMENTS By Type Monofocal Intraocular Lens Premium Intraocular Lens Toric Intraocular Lens Multifocal Intraocular Lens Accommodating Intraocular Lens Others Blue Light Filtering Intraocular Lens Phakic Intraocular Lens Aspheric Intraocular Lens By Material Polymethylmethacrylate (PMMA) Silicone Hydrophobic Acrylic By End User Hospitals Ambulatory Surgery Centers Ophthalmology Clinics Eye Research Institutes By Region North America U.S. Canada Mexico Europe Germany France UK Italy Spain Netherlands Norway Russia Sweden Switzerland Rest of Europe Asia-Pacific Japan China India Australia South Korea New Zealand Taiwan Thailand Rest of Asia-Pacific LAMEA Brazil Saudi Arabia South Africa Chile Columbia Egypt Iran Israel Turkey Venezuela Download the full report: https://www.reportbuyer.com/product/4883720/ About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: www.reportbuyer.com To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/multiplex-assays-market---global-opportunity-analysis-and-industry-forecast-2014-2022-300455547.html


LONDON, May 10, 2017 /PRNewswire/ -- miRNA Tools and Services Market by Product [Research Tools (Kits, Reagents, and Other Consumables) and Services (miRNA Extraction Services, Quantification Services, Microarray Services, Sequencing Services, Functional Studies Services, and Others)], Technology [Extraction Tools, qRT-PCR, NGS, Microarray, Functional Analysis Tools and Others], and End User (Research & Academic Institutes; IVD, Pharma & Biotech Companies; and CROs) - Global Opportunity Analysis and Industry Forecast, 2014-2022 Download the full report: https://www.reportbuyer.com/product/4883721/ miRNA is a set of small, non-coding RNA molecules that regulate gene expression post transcription. These molecules have an impact on a wide range of biological functions such as cell cycle control, stem cell differentiation, immune modulation, viral replication, and metabolic control. As the aforementioned processes are involved in the pathology of various diseases, tests performed on miRNAs help in disease treatment. Moreover, miRNAs can be easily manipulated than proteins, thus making them more useful for clinical diagnostics and therapeutics applications. The global miRNA tools and services market was valued at $146 million in 2015 and is expected to reach $620 million by 2022, growing at a CAGR of 23.4% during the forecast period. It is expected to witness significant growth owing to the rise in incidence of cancer, auto-immune, and cardiovascular diseases. In addition, miRNA molecules possess specific properties, such as higher tissue and organ specificity; and ability to cross the blood–brain barrier easily, that make them a favorable option to be used as biomarkers for a variety of neurological diseases, thereby driving the market growth. However, quantification challenges and development of in-use techniques, such as microarray, hamper the market growth. The global miRNA tools and services market is segmented on the basis of product, technique, end user, and geography. The miRNA tools and services market is bifurcated into research tools and services. Research tools market is further divided into reagents, kits, and consumables. On the other hand, the services market is classified into miRNA extraction services, quantification services, microarray services, sequencing services, functional studies services, and others. Based on techniques, the market is segmented into extraction tools, qRT-PCR, NGS, microarray, functional analysis tools (such as miRNA mimetics, inhibitors, and target site blockers), and others (such as labeling, ISH, and northern blotting tools). The end-user market is divided into research & academic institutes; IVD, pharma, and biotech companies; and CROs. The market is analyzed across four regions, namely, North America, Europe, Asia-Pacific, and LAMEA. Prominent players have adopted product development (including product launches and approvals) as their key developmental strategy to expand their product portfolio. For instance, in April 2010, NanoString Technologies, Inc. launched a new assay kit for miRNA analysis, which includes the multiplexed assay for profiling the human miRNA transcriptome in a single tube. This assay kit facilitates in direct digital detection and counting of miRNAs without the use of PCR amplification. KEY BENEFITS This report provides an extensive analysis of the current trends, emerging estimations, and dynamics in the global miRNA tools and services market from 2014 to 2022. Comprehensive analysis of all regions is provided to determine the prevailing market opportunities. It presents a detailed quantitative analysis and estimations to identify the prevailing opportunities. Comprehensive analysis of factors that drive and restrict the market growth is provided. Region- and country-wise market conditions are comprehensively analyzed. miRNA Tools and Services Market Key Segments By Product Research Tools Kits Reagents Other Consumables Services miRNA Extraction Services Quantification Services Microarray Services Sequencing Services Functional Studies Services Others By Technology Extraction Tools qRT-PCR NGS Microarray Functional Analysis Tools Others By End User Research & Academic Institutes IVD, Pharma, and Biotech Companies CROs By Region North America U.S. Canada Mexico Europe Germany France UK Italy Spain Russia Rest of Europe Asia-Pacific Japan China Australia India South Korea Taiwan Indonesia Thailand Rest of Asia-Pacific LAMEA Brazil Turkey Venezuela Saudi Arabia Republic of South Africa Colombia Argentina Download the full report: https://www.reportbuyer.com/product/4883721/ About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: www.reportbuyer.com To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mirna-tools-and-services-market---global-opportunity-analysis-and-industry-forecast-2014-2022-300455449.html


This report deals with cytogenetics in a broader sense rather than the classical use mainly to describe the chromosome structure and identify abnormalities related to disease. In the age of molecular biology, it is also referred to as molecular cytogenetics. The scope of cytogenetics includes several technologies besides fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and multicolor FISH. Molecular cytogenetics includes application of nanobiotechnology, microarrays, real-time polymerase chain reaction (PCR), in vivo imaging, and single molecule detection. Bioinformatics is described briefly as it plays an important role in analyzing data from many of these technologies. FISH remains the single most important technology in cytogenetics. Several innovations are described of which the most important are single copy FISH, in vivo FISH (imaging of nucleic acids in living cells) and nanotechnology-based FISH. The unique character of peptide nucleic acid (PNA) allows these probes to hybridize to target nucleic acid molecules more rapidly and with higher affinity and specificity compared with DNA probes. PNA-FISH is more suited for rapid diagnosis of infections. RNA-FISH and locked nucleic acids (LNAs), are also described. Microarray/biochip-based technologies for cytogenetics promise to speed up detection of chromosome aberrations now examined by FISH. Other important genomic technologies are whole genome expression array and direct molecular analysis without amplification. Analysis of single-cell gene expression promises a more precise understanding of human disease pathogenesis and has important diagnostic applications. Optical Mapping can survey entire human genomes for insertions/deletions, which account for a significantly greater proportion of genetic variation between closely-related genomes as compared to single nucleotide polymorphisms (SNPs), and are a major cause of gene defects. The report includes summary profiles of 69 companies relevant to cytogenetics along with their 80 collaborations. Companies developing innovative technologies as well as those supplying equipment/services/reagents are identified. The report text is supplemented with 27 Tables and 9 figures. Selected 200 references are included in the bibliography. Key Topics Covered: Executive Summary 1. Introduction 2. Technologies used for cytogenetics 3. Fluorescent In Situ Hybridization 4. Genomic Technologies relevant to Cytogenetics 5. Molecular Imaging & Single Molecular Detection 6. Role of Nanobiotechnology in Cytogenetics 7. Biomarkers and Cytogenetics 8. Applications of Cytogenetics 9. Cancer Cytogenetics 10. Cytogenetics Markets 11. Companies 12. References For more information about this report visit http://www.researchandmarkets.com/research/vzv3hl/cytogenetics Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-2017-cytogenetics-technologies-markets-and-companies-report---projections-to-2026-69-companies-with-80-collaborations---research-and-markets-300455435.html


— Market Highlights The North America microarray market has been evaluated as slowly growing market and expected to continue in the similar way in the near future. A microarray is a multiplex lab-on-a-chip. It is a 2D array on a solid substrate, usually a glass slide or silicon thin-film cell, that assays large amounts of biological material using high-throughput screening miniaturized, multiplexed and parallel processing and detection methods. Globally the Microarray Market is dominated by DNA microarrays. The protein microarray is currently the fastest growing market. The use of peptide and carbohydrate microarrays is expanding. Tissue and cell microarrays are in their infancy stage and are developing slowly because of many complications in the process development. Microarray is one of the methods which was used for the diagnostic purpose in cancer research. But commonly used types like DNA microarray, antibody array have not been proven to be effective methods in case of the disease like cancer. So in order to deal with the limitations of other types, tissue microarray was developed. Tissue microarray is an effective diagnostic tool for cancer diagnosis. The more and more research is going on to make the tissue microarray more accurate and efficient. As the prevalence of cancer is spreading, the growth in the tissue microarray method is expected in the future. North America Microarray Market Players: • ABCAM • Asterand Bioscience • IHC World LLC • Novus Biologicals LLC (Acquired By BIO-TECHNE) • Origene Technologies Inc • Pantomics, Inc • Protein Biotechnologies Inc • US Biomax, Inc. • US Bioupton Int • Vitrovivo Biotech, LLC On the other hand, as the technique is in its infancy stage, lots of mistakes and errors occur. The readings are not accurate many times. As the results are not reliable, it creates a hindrance in the growth of the tissue microarray method. Besides this, tissue microarrays are not recommended for certain types of studies. In certain tumors such as glioblastoma, there is such marked heterogeneity within tumors that this feature may not be adequately captured in tissue microarray studies. In addition, microarrays are also not very useful to study rare or focal events, such as number of immune cells in tumors. These are some of the factors that cause hindrance to the growth of the Tissue microarray market. Regional Analysis: North America tissue microarray market is segmented into two countries: United States, and Canada. U.S. is the largest market for tissue microarray. The U.S market for tissue microarray is expected to reach at USD 364.2 million by the end of the forecasted period. Canada is the second-largest market for tissue microarray which is expected to grow at a CAGR of 4.4%. Key Finding - The North America microarray market is expected to reach $1,635.4 billion by 2027. - Paraffin tissue sections (FFPE) hold the largest share of 54.6% of the North America Tissue Microarray market. - S. holds the largest market share of North America Tissue Microarray market and is anticipated to reach $364.2 million by the end of 2027. - Immunohistochemistry segment holds the largest market share of 47.5% in 2015. Segmentation: North America Microarray market has been segmented on the basis of types which comprises of protein microarray, tissue microarray, and cellular microarray. On the basis of product, North America Tissue microarray market is segmented into paraffin tissue sections (FFPE), frozen tissue sections, and others. On the basis of applications, tissue microarray market is segmented into immunohistochemistry, in-situ hybridization, and others. Intended Audience - Contract Research Organizations (CROs) - Research and Development (R&D) Companies - Government Research Laboratories - Independent Research Laboratories - Government and Independent Regulatory Authorities - Academic Institutes and Universities Related Report The global market for clinical data analytics is expected to reach USD 11,853.6 million by the end of the forecasted period and is expected to grow at a CAGR of 30.90%. https://www.marketresearchfuture.com/reports/clinical-data-analytics-market-2520 About Market Research Future: At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. For more information, please visit https://www.marketresearchfuture.com/reports/north-america-microarray-market-2641


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of Jain PharmaBiotech's new report "Cytogenetics - Technologies, Markets and Companies" to their offering. This report deals with cytogenetics in a broader sense rather than the classical use mainly to describe the chromosome structure and identify abnormalities related to disease. In the age of molecular biology, it is also referred to as molecular cytogenetics. The scope of cytogenetics includes several technologies besides fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and multicolor FISH. Molecular cytogenetics includes application of nanobiotechnology, microarrays, real-time polymerase chain reaction (PCR), in vivo imaging, and single molecule detection. Bioinformatics is described briefly as it plays an important role in analyzing data from many of these technologies. FISH remains the single most important technology in cytogenetics. Several innovations are described of which the most important are single copy FISH, in vivo FISH (imaging of nucleic acids in living cells) and nanotechnology-based FISH. The unique character of peptide nucleic acid (PNA) allows these probes to hybridize to target nucleic acid molecules more rapidly and with higher affinity and specificity compared with DNA probes. PNA-FISH is more suited for rapid diagnosis of infections. RNA-FISH and locked nucleic acids (LNAs), are also described. Microarray/biochip-based technologies for cytogenetics promise to speed up detection of chromosome aberrations now examined by FISH. Other important genomic technologies are whole genome expression array and direct molecular analysis without amplification. Analysis of single-cell gene expression promises a more precise understanding of human disease pathogenesis and has important diagnostic applications. Optical Mapping can survey entire human genomes for insertions/deletions, which account for a significantly greater proportion of genetic variation between closely-related genomes as compared to single nucleotide polymorphisms (SNPs), and are a major cause of gene defects. The report includes summary profiles of 69 companies relevant to cytogenetics along with their 80 collaborations. Companies developing innovative technologies as well as those supplying equipment/services/reagents are identified. The report text is supplemented with 27 Tables and 9 figures. Selected 200 references are included in the bibliography. For more information about this report visit http://www.researchandmarkets.com/research/9hr5g9/cytogenetics


Patent
Microarray Ltd | Date: 2017-02-08

A dressing comprising first and second electrodes, an electrical power supply, and further comprising a physiologically or antimicrobially active precursor substance, the dressing being operable, when placed on a skin site to be treated, for a first treatment period, whereby the electrochemical oxidation or reduction of the precursor substance on one of the electrodes to produce a physiologically active oxidised or reduced substance which is capable of diffusing towards the skin site for the treatment thereof is carried out, and subsequently for a first rest period, the electrochemical oxidation or reduction is stopped, wherein a subsequent treatment periods followed by rest periods are carried out over time.


A skin dressing comprising first and second electrodes, an electrical power supply not electrically connected to either or both of the first and second electrodes, and further comprising a physiologically or antimicrobially active precursor substance, the dressing being operable, when placed on a skin site to be treated, to connect the electrical power supply to both the first and second electrodes, thereby to trigger the electrochemical oxidation or reduction of the precursor substance on one of the electrodes to produce a physiologically or antimicrobially active oxidised or reduced compound which is capable of diffusing towards the skin site for the treatment thereof.


Patent
Microarray Ltd | Date: 2015-03-25

A dressing comprising first and second electrodes, an electrical power supply, and further comprising a physiologically or antimicrobially active precursor substance, the dressing being operable, when placed on a skin site to be treated, for a first treatment period, whereby the electrochemical oxidation or reduction of the precursor substance on one of the electrodes to produce a physiologically active oxidised or reduced substance which is capable of diffusing towards the skin site for the treatment thereof is carried out, and subsequently for a first rest period, the electrochemical oxidation or reduction is stopped, wherein subsequent treatment periods followed by rest periods are carried out over time.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Smart - Proof of Market | Award Amount: 24.95K | Year: 2012

Over the nine months of the project, we firstly intend to contact established companies within the field of water-testing (such as Hach, Palintest, Siemens) to introduce them to our technology and more importantly to ascertain their needs in terms of test requirements. Here we aim to gain an understanding of the tests currently employed by these major companies, with an emphasis being placed towards the more important analytes to be measured (for example total THM measurement, or individual species), the number of tests being taken, and also the accuracy at which the readings need to recorded. Once we have obtained this initial market research, we will then aim to use these preliminary meetings to provide further introductions to possible end-users of the technology. Here we aim to undertake a review of current measurement protocols so we can gain an in depth understanding of present techniques in terms of their limitations and un-met needs. We will then use these findings as a starting point on which to further expand our development protocols. As our final aim is to possibly provide a device which is capable of measurement of a number of different analytes (such as CHCl3, CHBrCl2, CHBr2Cl and CHBr3), we feel it is important to gain an in-depth knowledge of what is required at the user interface. Input from end-users is vital for us to develop a device which is commercially viable. We already have identified THMs as a possible target analyte; however we also seek information regarding specific THM species for us to develop defined measurement protocols. Differing disinfection protocols will lead to the formation of increased levels of particular THM species (such as increased CHBr3 levels when bromination is employed). Once we have taken advice from end users, we can then implement an investigation into time-scales and costings for the development of sensing devices for each of the required analytes. We already have in place a rudimentary ‘proof-of-concept’ development of the methodology required for the determination of one THM species, chloroform. For the determination of chloroform a simple electrochemical technique is employed, upon carbon screen-printed surface that have been modified to microelectrode arrays via our novel fabrication procedures. The measurement protocol is based on the oxidation of the chloroform species on a reverse anodic sweep, where an oxidation peak current is detected and can be related back to the concentration under investigation. To date we have measured down to levels of 1ppm, but we know we need to obtain lower limits of detection in the order of ~80ppm and we require further guidance as to the lower limits of detection required for specific THMs; we intend to obtain this information and further guidance from meetings with potential end users and contacts at each of the highlighted companies. We would also need to investigate our freedom to seek patent protection for our approach process. We would also begin to establish whether specific components of any possible product, could be protected to gain maximum protection. This exercise will also help us identify any competing patents or other obstacles to allow commercialisation. Patents within the infringement period that are not in force, but which may clear a ‘right-to-use’ by virtue of being in the public domain, will also be searched for. When this type of search is followed up with a validity search against any highly relevant patents identified, this is sometimes referred as a clearance search.


Patent
Microarray Ltd | Date: 2012-08-10

This invention relates to improvements to medical devices such as biosensors containing proteins such as oxidoreductases, for example oxidase and/or peroxidase enzymes. More generally it relates to novel compositions containing proteins which are stabilised to ionising radiation.

Loading Microarray Ltd collaborators
Loading Microarray Ltd collaborators